Management Quality -- 4/10
DEO scores a 4 on management quality. CEO Debra Crew departed after roughly two years (mid-2023
to mid-2025), CFO Lavanya Chandrashekar was replaced by Nik Jhangiani in Sep 2024, and by FY2025
Jhangiani was serving as interim CEO with yet another interim CFO (Deirdre Mahlan) incoming.
Promise delivery is poor at 33% (4 of 12 met). Medium-term guidance of 5-7% organic net sales
growth was formally withdrawn, the 25-year dividend increase streak was broken, leverage
deteriorated above target range to 3.4x, and $1.4B in exceptional impairments were booked in
FY2025. Solid FCF generation and LAC inventory resolution demonstrate some execution capability,
but the overall record is weak.
Weight: 20%
CEO
Nik Jhangiani (Interim, since mid-2025)
3rd leadership change in 18 months | Interim CFO Deirdre Mahlan
Promise Delivery
4 of 12 Met (33%)
Well below 60% threshold | Medium-term guidance formally withdrawn
Leverage
3.4x Debt/EBITDA (above 2.5-3.0x target)
Rose from 2.9x to 3.4x | Management says FY2028 to return to range
Red Flags
4 Confirmed
CEO/CFO churn, guidance withdrawn, failed M&A, debt outpacing revenue
Leadership team
Nik Jhangiani -- Interim CEO (since mid-2025)
Joined as CFO in Sep 2024, then elevated to interim CEO following Debra Crew departure
in mid-2025. Previously CFO at Coca-Cola HBC. Third leadership change in 18 months.
The rapid succession of CEO/CFO changes reflects instability at the top of the
organization. The board has not yet announced a permanent CEO.
Debra Crew -- Former CEO (mid-2023 to mid-2025)
Appointed CEO after Ivan Menezes stepped down in mid-2023. Tenure lasted roughly
two years. During her leadership, guidance was repeatedly downgraded, medium-term
targets were formally withdrawn, the dividend streak was broken, and leverage
deteriorated above target range. Departed without delivering on the core growth
promises inherited from the Menezes era.
Deirdre Mahlan -- Incoming Interim CFO
Announced as interim CFO following Jhangiani moving to the interim CEO role.
The fact that both C-suite positions are now filled by interim leaders underscores
the depth of the leadership vacuum. Capital allocation decisions and strategic
direction are effectively on hold until permanent appointments are made.
Promise tracking (12 promises)
| # | Promise | When | Target | Actual Result | Verdict |
|---|---|---|---|---|---|
| 1 | Medium-term organic NSV growth of 5-7% | H1 FY2023 (Menezes) | 5-7% organic net sales growth | FY2024: -0.6%; FY2025: +1.7%; guidance formally withdrawn at H1 FY2025. | MISS |
| 2 | Organic operating profit growth in line with NSV | H1 FY2023 | Op profit broadly tracks NSV growth | FY2024: organic op margin -130bps; FY2025: organic op profit -0.7%. Never returned to algo. | MISS |
| 3 | Stronger FCF in H2 FY2023 | H1 FY2023 (Menezes) | FCF improvement in H2 | FCF did improve in H2 FY2023 (company reported strong FCF for full year). | HIT |
| 4 | $1.5B three-year productivity savings by end FY2024 | H1 FY2023 | $1.5B cumulative savings | Delivered $1.7B, exceeding the $1.5B target. | HIT |
| 5 | Normalize LAC inventories by end FY2024 | H1 FY2024 (Crew) | LAC inventories at appropriate levels | Achieved -- LAC inventories normalized by FY2024 year-end. | HIT |
| 6 | LAC H2 FY2024 organic NSV decline of 10-20% | H1 FY2024 | Managed decline in 10-20% range | Full-year LAC organic NSV -21.1%, implying H2 roughly in guided range. | HIT |
| 7 | Organic NSV to gradually improve in H2 FY2024 vs H1 | H1 FY2024 | Sequential improvement in growth rate | Full-year organic NSV was -0.6% (same as H1), suggesting negligible improvement at group level. | MISS |
| 8 | FY2025 organic op profit broadly in line with NSV | H1 FY2024, FY2024 | Op profit tracks NSV growth | FY2025 organic op profit -0.7% while organic NSV +1.7%. Op profit did not grow in line. | MISS |
| 9 | Progress toward medium-term guidance in FY2025 | FY2023, H1 FY2024 | Improving trajectory toward 5-7% | NSV went from -0.6% to +1.7% -- improved but far below 5-7%. Target withdrawn. | MISS |
| 10 | Leverage ratio maintained at 2.5-3.0x | H1 FY2024, FY2024 | Stay within or return to range | FY2024: 3.0x, H1 FY2025: 3.1x, FY2025: 3.4x, H1 FY2026: 3.4x -- above range, worsening. | MISS |
| 11 | 5% progressive dividend increase | H1 FY2024, FY2024 | Continue 25-year dividend growth streak | Dividend held flat in FY2025 (broke 25-year streak of increases). | MISS |
| 12 | $2B productivity savings over FY2025-FY2027 | H1 FY2024 | $2B cumulative savings | Replaced by Accelerate program ($625M over 3 years); original $2B target effectively abandoned. | MISS |
12 promises tracked. 4 HIT (H2 FY2023 FCF, productivity savings exceeded $1.5B target, LAC inventory
normalization, LAC H2 decline in guided range). 8 MISS (medium-term growth guidance, operating profit
alignment, H2 FY2024 improvement, FY2025 op profit, progress toward targets, leverage, dividend streak,
$2B productivity target). Hit rate of 33% is well below the 60% threshold.
Source: Earnings call transcripts H1 FY2023 through H1 FY2026, Daloopa.
Actuals summary
| Metric | H1 FY2024 | FY2024 | H1 FY2025 | FY2025 | H1 FY2026 |
|---|---|---|---|---|---|
| Net Sales ($M) | $10,962 | $20,269 | $10,901 | $20,245 | $10,460 |
| Operating Profit ($M) | $3,317 | $6,001 | $3,155 | $4,335 | $3,116 |
| Free Cash Flow ($M) | $1,462 | $2,609 | $1,696 | $2,748 | $1,532 |
| EPS Pre-Except (pence) | 108.1p | 179.6p | 97.7p | 164.2p | 95.3p |
| Operating Margin | 30.3% | 29.6% | 29.0% | ~21.4% | N/A |
| Debt/EBITDA | 2.9x | 3.0x | 3.1x | 3.4x | 3.4x |
Data sourced from Daloopa.
Positive notes (why not lower)
Productivity Savings Exceeded Target
Delivered $1.7B against the $1.5B three-year productivity savings target by FY2024. This
was one of the few areas where management over-delivered. The new Accelerate program
($625M over 3 years) shows continued cost discipline, even if the original $2B target
was quietly replaced with a smaller figure.
LAC Inventory Resolution
Management promised to normalize Latin America and Caribbean inventories by end of
FY2024 and delivered. The guided range of 10-20% H2 decline was also roughly met.
This demonstrated the ability to execute on specific, measurable operational targets
even while broader strategy was faltering.
Solid FCF Generation
Free cash flow improved from $2.6B (FY2024) to $2.7B (FY2025) despite flat-to-declining
revenue. The business continues to generate substantial cash, which provides a floor
under the equity and supports the dividend even without growth. FCF resilience is the
strongest argument against a lower score.
Red flags assessment
| Red Flag | Status | Detail |
|---|---|---|
| CEO/CFO change in last 2 years | YES | CEO Debra Crew departed mid-2025 (~2 years in role). CFO replaced Sep 2024. Interim CEO and interim CFO currently in place. Three leadership changes in 18 months. |
| Guidance withdrawn | YES | Medium-term guidance of 5-7% organic NSV growth formally removed at H1 FY2025 results (Feb 2025). |
| Restatements | NO | No accounting restatements identified. |
| Insider selling >$10M | NOT CONFIRMED | No evidence in transcripts of significant insider selling, but not verifiable from transcripts alone. |
| Revenue growing but FCF declining | MIXED | Revenue flat FY2024-FY2025. FCF improved. However, H1 FY2026 net sales down to $10.5B while FCF also lower at $1.5B vs $1.7B prior year H1. |
| Failed M&A / impairments | YES | $450M Distill Ventures impairment in FY2025. $230M Aviation Gin impairment. Various brand write-downs. Total exceptionals $1.4B in FY2025. |
| Debt growing faster than revenue | YES | Revenue flat-to-declining. Leverage increased from 2.9x to 3.4x, well above target range. Net debt increased $0.8B in FY2025. |
4 confirmed red flags: (1) extreme CEO/CFO churn with both positions now interim; (2) medium-term
guidance formally withdrawn after years of missing it; (3) $1.4B in exceptional impairments from
failed M&A (Distill Ventures, Aviation Gin); (4) leverage deteriorating above target range with
no near-term path back. This is a significantly elevated red flag count for a global consumer staples
company.
Key weaknesses
Leadership Vacuum
Two CEO transitions and two CFO transitions in the last two years. Both the CEO and CFO
roles are currently filled by interim appointments. This level of C-suite churn is
exceptional for a company of this scale and pedigree. Strategic direction is effectively
on hold, and capital allocation decisions lack the authority of permanent leadership.
Guidance Credibility Destroyed
Medium-term guidance of 5-7% organic NSV growth was reiterated multiple times before
being formally withdrawn in Feb 2025 after years of missing it. The $2B productivity
target was replaced with a smaller program. The 25-year dividend increase streak was
broken. New management will need to rebuild credibility from scratch.
Balance Sheet Deterioration
Leverage rose from 2.9x to 3.4x (above the 2.5-3.0x target range), with management
acknowledging it will take until FY2028 to return within range. Net debt increased
$0.8B in FY2025 despite flat revenue. This limits strategic flexibility and constrains
the ability of new leadership to invest in growth or return capital.
Material M&A Impairments
$1.4B in exceptional charges in FY2025 including $450M Distill Ventures impairment
and $230M Aviation Gin impairment. These write-downs reflect poor capital allocation
decisions from the prior leadership era. The magnitude is significant relative to the
$4.3B FY2025 operating profit (including exceptionals).
Score rationale
4/10. Diageo management has navigated a prolonged post-COVID normalization cycle
with limited success. The promise hit rate of 33% (4 of 12) is well below the 60% threshold.
Leadership instability is extreme -- two CEO transitions and two CFO transitions in two years,
with both roles currently filled by interim appointments. Medium-term guidance was formally
withdrawn after years of missing it, the 25-year dividend increase streak was broken, and
leverage deteriorated above target range to 3.4x. Four red flags are confirmed.
Why not lower (2-3): FCF generation remains solid ($2.7B in FY2025), the productivity savings program exceeded its $1.5B target, and LAC inventory normalization was delivered as promised. The business continues to generate substantial cash and market share improved in H1 FY2025/FY2025. These execution points prevent a bottom-tier score.
What would move this higher: Permanent CEO and CFO appointments with a credible track record. Re-establishment of medium-term financial targets that are actually achieved. Leverage returning toward the 2.5-3.0x target range. Resumption of organic net sales growth approaching mid-single digits. Until these conditions are met, the management dimension will remain a drag on the composite score.
Why not lower (2-3): FCF generation remains solid ($2.7B in FY2025), the productivity savings program exceeded its $1.5B target, and LAC inventory normalization was delivered as promised. The business continues to generate substantial cash and market share improved in H1 FY2025/FY2025. These execution points prevent a bottom-tier score.
What would move this higher: Permanent CEO and CFO appointments with a credible track record. Re-establishment of medium-term financial targets that are actually achieved. Leverage returning toward the 2.5-3.0x target range. Resumption of organic net sales growth approaching mid-single digits. Until these conditions are met, the management dimension will remain a drag on the composite score.
Data sourced from Daloopa and earnings call transcripts H1 FY2023 through H1 FY2026.